Design and Synthesis of a MAO‐B‐Selectively Activated Prodrug Based on MPTP: A Mitochondria‐Targeting Chemotherapeutic Agent for Treatment of Human Malignant Gliomas

Malignant gliomas, including glioblastomas, are extremely difficult to treat. The median survival for glioblastoma patients with optimal therapeutic intervention is 15 months. We developed a novel MAO‐B‐selectively activated prodrug, N,N‐bis(2‐chloroethyl)‐2‐(1‐methyl‐1,2,3,6‐tetrahydropyridin‐4‐yl)propanamide (MP‐MUS), for the treatment of gliomas based on 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP). The design of neutral MP‐MUS involved the use of a seeker molecule capable of binding to mitochondrial MAO‐B, which is up‐regulated ≥fourfold in glioma cells. Once the binding occurs, MP‐MUS is converted into a positively charged moiety, P+‐MUS, which accumulates inside mitochondria at a theoretical maximal value of 1000:1 gradient. The LD50 of MP‐MUS against glioma cells is 75 μM, which is two‐ to threefold more potent than temozolomide, a primary drug for gliomas. Importantly, MP‐MUS was found to be selectively toxic toward glioma cells. In the concentration range of 150–180 μM MP‐MUS killed 90–95 % of glioma cells, but stimulated the growth of normal human astrocytes. Moreover, maturation of MP‐MUS is highly dependent on MAO‐B, and inhibition of MAO‐B activity with selegiline protected human glioma cells from apoptosis.

[1]  R. M. Rose,et al.  Distinct monoamine oxidase A and B populations in primate brain. , 1985, Science.

[2]  Edward Chu,et al.  A history of cancer chemotherapy. , 2008, Cancer research.

[3]  L. Callado,et al.  Monoamine oxidase B activity is increased in human gliomas , 2008, Neurochemistry International.

[4]  K. Chan,et al.  Kinetics of phosphoramide mustard hydrolysis in aqueous solution. , 1985, Journal of pharmaceutical sciences.

[5]  C. Franceschi,et al.  JC‐1, but not DiOC6(3) or rhodamine 123, is a reliable fluorescent probe to assess ΔΨ changes in intact cells: implications for studies on mitochondrial functionality during apoptosis , 1997, FEBS letters.

[6]  J. Finberg.  Update on the pharmacology of selective inhibitors of MAO-A and MAO-B: focus on modulation of CNS monoamine neurotransmitter release. , 2014, Pharmacology & therapeutics.

[7]  T. Roszman,et al.  Suppression of high affinity IL-2 receptors on mitogen activated lymphocytes by glioma-derived suppressor factor , 1992, Journal of Neuro-Oncology.

[8]  G. Engberg,et al.  Deprenyl (selegiline), a selective MAO-B inhibitor with active metabolites; effects on locomotor activity, dopaminergic neurotransmission and firing rate of nigral dopamine neurons. , 1991, The Journal of pharmacology and experimental therapeutics.

[9]  E. Niki,et al.  1‐Methyl‐4‐phenyl‐2,3‐dihydropyridinium is transformed by ubiquinone to the selective nigrostriatal toxin 1‐methyl‐4‐phenylpyridinium , 1999, FEBS letters.

[10]  M. Vila,et al.  Localization of monoamine oxidases in human peripheral tissues. , 1996, Life sciences.

[11]  R. M. Rose,et al.  Localization of distinct monoamine oxidase a and monoamine oxidase b cell populations in human brainstem , 1988, Neuroscience.

[12]  P. Mander,et al.  Fibrillar beta-amyloid peptide Aβ1–40 activates microglial proliferation via stimulating TNF-α release and H2O2 derived from NADPH oxidase: a cell culture study , 2006, Journal of Neuroinflammation.

[13]  P. Lampen,et al.  In vivo intracerebral microdialysis studies in rats of MPP+ (1-methyl-4-phenylpyridinium) analogs and related charged species , 1990 .

[14]  Andrea Mattevi,et al.  Three-dimensional structure of human monoamine oxidase A (MAO A): relation to the structures of rat MAO A and human MAO B. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[15]  C. Franceschi,et al.  A new method for the cytofluorimetric analysis of mitochondrial membrane potential using the J-aggregate forming lipophilic cation 5,5',6,6'-tetrachloro-1,1',3,3'-tetraethylbenzimidazolcarbocyanine iodide (JC-1). , 1993, Biochemical and biophysical research communications.

[16]  H. Pollard,et al.  Contrasting monoamine oxidase activity and tyramine induced catecholamine release in PC12 and chromaffin cells , 1986, Neuroscience.

[17]  Yang Zhou,et al.  Optical Imaging of Tumors with Copper-Labeled Rhodamine Derivatives by Targeting Mitochondria , 2012, Theranostics.

[18]  Alan A. Wilson,et al.  Distribution of Monoamine Oxidase Proteins in Human Brain: Implications for Brain Imaging Studies , 2013, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[19]  L. Deangelis,et al.  Glioblastoma and other malignant gliomas: a clinical review. , 2013, JAMA.

[20]  J. Rey,et al.  Effect of lomeguatrib–temozolomide combination on MGMT promoter methylation and expression in primary glioblastoma tumor cells , 2013, Tumor Biology.

[21]  J. Villano,et al.  Long-term treatment with temozolomide in malignant glioma , 2014, Journal of Clinical Neuroscience.

[22]  A. Brossi,et al.  Metabolism of the neurotoxin in MPTP by human liver monoamine oxidase B , 1985, FEBS letters.

[23]  Eric Gouaux,et al.  X-ray structure of dopamine transporter elucidates antidepressant mechanism , 2013, Nature.

[24]  L. Galluzzi,et al.  Mitochondria as therapeutic targets for cancer chemotherapy , 2006, Oncogene.

[25]  G. Meredith,et al.  MPTP mouse models of Parkinson's disease: an update. , 2011, Journal of Parkinson's disease.

[26]  Andrea Mattevi,et al.  Crystal structures of monoamine oxidase B in complex with four inhibitors of the N-propargylaminoindan class. , 2004, Journal of medicinal chemistry.

[27]  H. Weinstein,et al.  The binding sites for cocaine and dopamine in the dopamine transporter overlap , 2008, Nature Neuroscience.

[28]  R. Stupp,et al.  Current concepts and management of glioblastoma , 2011, Annals of neurology.

[29]  R. Ramsay,et al.  Substrate-specific enhancement of the oxidative half-reaction of monoamine oxidase. , 1993, Biochemistry.

[30]  P. Sinko,et al.  Recent trends in targeted anticancer prodrug and conjugate design. , 2008, Current medicinal chemistry.

[31]  R. Haugland,et al.  A stable nonfluorescent derivative of resorufin for the fluorometric determination of trace hydrogen peroxide: applications in detecting the activity of phagocyte NADPH oxidase and other oxidases. , 1997, Analytical biochemistry.

[32]  L. Pearce,et al.  Human brain monoamine oxidase: solubilization and kinetics of inhibition by octylglucoside. , 1983, Archives of biochemistry and biophysics.

[33]  C. Williams.  Monoamine oxidase. I. Specificity of some substrates and inhibitors. , 1974, Biochemical pharmacology.

[34]  Abhigna Polavarapu,et al.  The mechanism of guanine alkylation by nitrogen mustards: a computational study. , 2012, The Journal of organic chemistry.

[35]  N. Freedman,et al.  In vivo measurement of brain monoamine oxidase B occupancy by rasagiline, using (11)C-l-deprenyl and PET. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[36]  K. Tipton,et al.  Uptake and accumulation of 1-methyl-4-phenylpyridinium by rat liver mitochondria measured using an ion-selective electrode. , 1992, The Biochemical journal.

[37]  N. Castagnoli,et al.  Potential latent nitrogen mustard derivatives designed to target monoamine oxidase rich cells. , 1997, Bioorganic & medicinal chemistry.

[38]  X. Breakefield,et al.  Immunocytochemical demonstration of monoamine oxidase B in brain astrocytes and serotonergic neurons. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[39]  Erwan Bezard,et al.  Modeling Parkinson's disease in primates: The MPTP model. , 2012, Cold Spring Harbor perspectives in medicine.

[40]  Andrea Mattevi,et al.  Insights into the mode of inhibition of human mitochondrial monoamine oxidase B from high-resolution crystal structures , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[41]  F. Guengerich,et al.  Metabolism of 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine by Mitochondrion-targeted Cytochrome P450 2D6 , 2012, The Journal of Biological Chemistry.

[42]  R. Wheelhouse,et al.  Glioblastoma Multiforme Therapy and Mechanisms of Resistance , 2013, Pharmaceuticals.

[43]  J. Shih,et al.  Monoamine oxidase: from genes to behavior. , 1999, Annual review of neuroscience.

[44]  D. Edmondson,et al.  Structure-activity relationships in the oxidation of para-substituted benzylamine analogues by recombinant human liver monoamine oxidase A. , 1999, Biochemistry.